New advancements improve early cancer detection tests
最新進展提升了癌症早期檢測的準確性
A significant paradigm shift is transforming oncology, moving from reactive, invasive procedures toward proactive, non-invasive early cancer detection.
腫瘤學正面臨一場重大的典範轉移，正從被動且侵入性的治療程序，轉向主動且非侵入性的早期癌症檢測。
Central to this evolution is the liquid biopsy, a revolutionary technology that analyzes biological fluids like blood to identify circulating tumor DNA and other molecular footprints.
這場演變的核心在於「液態切片」（ㄧㄝˋㄊㄞˋㄑㄧㄝˋㄆㄧㄢˋ），這是一項革命性的技術，透過分析血液等生物體液，以識別循環腫瘤DNA及其他分子足跡。
By shifting from traditional tissue samples to simple blood draws, doctors can now employ Multi-Cancer Early Detection (MCED) tests to screen for dozens of cancer types simultaneously.
藉由將傳統的組織採樣轉變為簡單的抽血，醫生現在能運用「多癌早期檢測」（MCED）篩檢技術，同時檢測數十種癌症。
Parallel to this, Artificial Intelligence (AI) is acting as a powerful catalyst.
與此同時，人工智慧（AI）正扮演著強大的催化劑。
AI enhances the accuracy of radiology and pathology imaging while also developing molecular sensors that may one day enable simple, at-home screenings.
AI不僅能提高放射影像與病理影像的準確度，還能研發出分子感測器，或許有朝一日能實現居家簡易篩檢。
Furthermore, large-scale clinical trials are essential to ensure these innovations truly reduce mortality rates rather than just creating unnecessary medical interventions.
此外，大規模的臨床試驗對於確保這些創新技術真正能降低死亡率，而非僅是造成不必要的醫療介入至關重要。
